Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer
Recruiting · NCT04136782 · Registry updated 2021-07-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 4 | 2021-07-20 | NCT04136782 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shengjing Hospital | 111 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital Affiliated to Harbin Medical University | Harbin | China | 3 |
| Dalian Municipal Central Hospital | Dalian | China | 3 |
| Liaoning Cancer Hospital & Institute | Shenyang | China | 16 |
| Panjin Liaohe Oilfield Gem Flower Hospital | Panjin | China | 2 |
| Shengjing Hospital Of China Medical University | Shenyang | China | 54 |
| The Fourth Affiliated Hospital of China Medical University | Shenyang | China | 8 |
| The Second Hospital of Jilin University | Changchun | China | 10 |